Get access

Similar effects of recombinant interferon-α-2b and natural interferon-α when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma

Authors

  • Kiminori Uka,

    1. Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
    Search for more papers by this author
  • Hiroshi Aikata,

    1. Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
    Search for more papers by this author
  • Shintaro Takaki,

    1. Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
    Search for more papers by this author
  • Daiki Miki,

    1. Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
    Search for more papers by this author
  • Soo Cheol Jeong,

    1. Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
    Search for more papers by this author
  • Akira Hiramatsu,

    1. Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
    Search for more papers by this author
  • Hideaki Kodama,

    1. Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
    Search for more papers by this author
  • Hiroo Shirakawa,

    1. Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
    Search for more papers by this author
  • Yoshiiku Kawakami,

    1. Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
    Search for more papers by this author
  • Shoichi Takahashi,

    1. Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
    Search for more papers by this author
  • Naoyuki Toyota,

    1. Department of Radiology, Hiroshima University Hospital, Hiroshima, Japan
    Search for more papers by this author
  • Katsuhide Ito,

    1. Department of Radiology, Hiroshima University Hospital, Hiroshima, Japan
    Search for more papers by this author
  • Kazuaki Chayama

    1. Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
    Search for more papers by this author

Correspondence
Hiroshi Aikata, MD, Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
Tel: +81 82 257 5192
Fax: +81 82 257 5194
e-mail: aikata@hiroshima-u.ac.jp

Abstract

Aim: Intra-arterial 5-fluorouracil (5-FU) plus interferon (IFN) combination therapy is effective against advanced hepatocellular carcinoma (HCC) with portal vein tumour thrombosis. In this study, we compared the efficiency and safety of recombinant IFN-α-2b with natural IFN-α as components of the combination therapy.

Methods: Consecutive HCC patients (n=31) with portal vein tumour thrombosis were enrolled in this prospective study. They received combination therapy of 5-FU and either recombinant IFN-α-2b (R group, n=15) or natural IFN-α (N group, n=16). We compared the two groups for the early response rate, adverse reactions, time to progression (TTP) and survival rates. In addition, we assessed the cost-effectiveness of each protocol.

Results: The early response rate (R: 26.7%, N: 31.2%), median TTP (R: 5.8 months, N: 5.6 months) and median survival time (R: 7.5 months, N: 6.5 months) were not significantly different between the R and N groups. There were no differences in adverse reactions between the two groups. The estimated cost-effectiveness ratio of recombinant IFN-α-2b was better than natural IFN-α.

Conclusions: In our protocol of combination therapy, there were no significant differences between recombinant IFN-α-2b and natural IFN-α with regard to early response to therapy, adverse effects, TTP and survival rates. 5-FU could be combined with either recombinant IFN-α-2b or natural IFN-α, although the cost-effectiveness of the former warrants its use clinically.

Get access to the full text of this article

Ancillary